Welcome to our dedicated page for Achieve Life Sciences SEC filings (Ticker: ACHV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Achieve Life Sciences SEC filings document current reports on operating results, cytisinicline development updates, governance matters, material agreements, and capital-structure disclosures. Recent Form 8-K filings include furnished financial-results releases and business updates tied to the company’s late-stage specialty pharmaceutical focus on cytisinicline for nicotine dependence.
The filing record also covers executive and board changes, compensatory arrangements, consulting and separation agreements, shareholder voting matters, security-structure disclosures, and clinical or regulatory disclosures related to the cytisinicline program. These filings provide formal records of the company’s corporate events, financial-condition updates, and governance actions as a public biotechnology issuer.
Achieve Life Sciences is asking stockholders to approve four key items at its 2026 virtual annual meeting on July 2, 2026. Stockholders will vote on electing nine directors, ratifying PricewaterhouseCoopers as auditor for 2026, and a non-binding “Say on Pay” vote on executive compensation.
The company also seeks to amend its certificate of incorporation to increase authorized common stock from 150,000,000 to 300,000,000 shares. As of May 15, 2026, 102,659,057 shares were outstanding and all authorized common stock was either issued or reserved, including large warrant and equity plan reserves tied to the June 2025 public offering and April 2026 private placement.
The proxy outlines board structure, committee responsibilities, director independence and compensation, related-party arrangements, and prior financings that raised approximately $45.0 million in June 2025 and $180.0 million in April 2026, largely through common stock, pre-funded warrants and accompanying common warrants.
Achieve Life Sciences director Reid Alexander Waldman received a new stock option grant, giving him the right to buy 47,250 shares of common stock at an exercise price of $5.24 per share. These options vest in substantially equal monthly installments over 36 months starting on May 29, 2026, so the award becomes available gradually as he continues serving the company.
The options expire on May 29, 2036 if not exercised, and this grant brings Waldman’s total reported option holdings from this award to 47,250 derivative securities. The transaction is compensation-related rather than an open-market purchase or sale of existing shares.
ACHIEVE LIFE SCIENCES, INC. reported that director Jeffrey S. Farrow received a grant of stock options. The award covers 47,250 shares of common stock at an exercise price of $5.24 per share, expiring on May 29, 2036. Following the grant, he holds options for 47,250 underlying shares. The options will vest in substantially equal monthly installments over 36 months starting May 29, 2026, as long as he continues providing services to the company on each vesting date.
ACHIEVE LIFE SCIENCES, INC. director Reid Alexander Waldman filed an initial Form 3 reporting his ownership position in the company. The filing shows that no securities are beneficially owned, with 0 shares held directly after the reporting date. This is a disclosure of status rather than a new transaction.
Achieve Life Sciences director Jeffrey S. Farrow has filed an initial Form 3 indicating he currently holds no company securities. The filing lists “No securities are beneficially owned,” with total shares following the reported status shown as 0. This establishes his baseline ownership disclosure as a director of Achieve Life Sciences.
Achieve Life Sciences is expanding its board by appointing Jeff Farrow and Reid Waldman, M.D. as directors, effective May 29, 2026. They will also serve in key committee leadership roles, including chairing the Audit Committee and the Compensation Committee.
Under the company’s non-employee director compensation program, each new director will receive a pro-rated $40,000 cash retainer for the fiscal year ending December 31, 2026, plus additional cash compensation for committee service. Each will also receive a stock option to purchase 47,250 shares of common stock, vesting monthly over three years, subject to continued service.
Achieve Life Sciences, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held virtually on July 2, 2026, where shareholders will vote on director elections, ratification of PricewaterhouseCoopers LLP, a non-binding advisory "Say-on-Pay" and a proposal to amend the charter to increase authorized common shares from 150,000,000 to 300,000,000.
The proxy statement states the record date is May 15, 2026 and that 102,659,057 shares of common stock were outstanding as of that date. The Board recommends voting FOR each nominee, for ratification of PwC, for approval of executive compensation, and for the authorized-share increase described in Proposal Four.
ACHIEVE LIFE SCIENCES, INC. director Martin Christopher Nathan received a grant of stock options covering 47,250 shares of Common Stock. The options have an exercise price of $5.59 per share and expire on May 11, 2036.
The award was provided as compensation and is held directly. According to the terms, the option will vest in substantially equal monthly installments over 36 months starting on May 11, 2026, as long as Nathan continues to provide service to the company on each vesting date.